Stellar Biotechnologies Inc. (SBOTF)

[chadcmb]

Dear Stellar Supporter:

We are pleased to report that a second scientific abstract representing the Company’s KLH active immunotherapy program on Clostridium difficile infection (“C. diff”) has been accepted for presentation at the 7th Vaccine & ISV Congress to be held October 27-29, 2013 in Barcelona, Spain.

The poster will be titled “Immunization with Clostridium difficile PSII polysaccharide antigens adjuvanted with KLH induced broad-based enhancement of adaptive immune responses and protection in mice.”

This will be the second of two presentations this month related to Stellar’s C. diff immunotherapy program:

October 22-26, 2013 – ClostPath 8 Conference, Queensland, Australia – Preclinical Oral Presentation

October 27-29, 2013 – 7th Vaccine & ISV Congress, Barcelona, Spain – Preclinical Poster

These presentations are indicative of the development being generated under Stellar’s newly acquired, exclusive license to active immunotherapy technology for the treatment and diagnosis of Clostridium difficile. Stellar’s scientists are working closely with researchers at the University of Guelph (Ontario, Canada) to advance this program.

About Clostridium difficile

Clostridium difficile is a major and growing cause of mortality and morbidity in hospitalized patients. Incidence of C. diff is at a record high in the U.S. with more than 330,000 cases reported in 2009. C. diff is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. It causes severe diarrhea and life-threatening intestinal conditions such as colitis. The cost of C. diff related treatment in the U.S. and Europe is estimated at more than $7 billion annually.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/

Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.



Contacts:

Frank Oakes, Chairman
Phone [phone]

[e-mail]

Investor Relations:
MZ Group
Mark A. McPartland
Senior Vice President
Phone: [phone]
[e-mail]
Web: www.mzgroup.us

Forward Looking Statements
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.